Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Panel Approves 5 COVID Vaccines for NIP Use from October
Japan’s health ministry panel on September 5 approved the use of five COVID-19 vaccines under the national immunization program (NIP) for the current fiscal year, starting in October. The same five vaccines — Pfizer, Moderna, Daiichi Sankyo, Takeda Pharmaceutical, and…
To read the full story
Related Article
- Moderna Launches LP.8.1-Adapted Spikevax for Ages 6 Months to 11 Years
October 15, 2025
- Meiji Rolls Out 2-Dose Vial of COVID-19 Vaccine Kostaive
September 29, 2025
- Moderna Rolls Out LP.8.1-Tailored Spikevax in Japan
September 24, 2025
- Japanese Medical Societies Strongly Recommend COVID Vaccinations from October
September 3, 2025
- Japan Expects COVID Vaccine Supply of 9 Million Doses in 2025-26
September 1, 2025
- Meiji Bags Japan Approval for 2-Dose COVID Vaccine Vial
September 1, 2025
- LP.8.1-Tailored Nuvaxovid COVID Jab Approved in Japan: Takeda
August 28, 2025
- Japan Approves Pfizer/BioNTech’s LP.8.1-Tailored COVID Vaccines
August 12, 2025
- Japan Approves Updated Spikevax for LP.8.1 Omicron Strain
August 6, 2025
- Japan Selects JN.1 Substrains for COVID Vaccines in 2025-2026 Season
May 30, 2025
- Japan Govt Ends Subsidies for COVID Vaccinations from FY2025
April 14, 2025
REGULATORY
- MOF Pushes for Full-Scale FY2027 Off-Year Drug Price Revision Ahead of “Spring” Proposal
April 28, 2026
- Japan Panel Backs Boehringer’s IPF Drug, Moderna COVID Vaccine
April 28, 2026
- Japan Allows Flexibility on Pharmacopoeia Test Differences in Supply Crunch
April 28, 2026
- Zepbound in Line for OSA Approval after Key Panel Nod
April 27, 2026
- LDP Team Urges Patent-Period Price Maintenance, CEA Review in Growth Strategy Proposal
April 27, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…